PriceTargets.com logo

LumiraDx - LMDX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.75
  • Forecasted Upside: ∞
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 01/9/2024 12:59 AM ET
+0 (0.00%)
Get New LumiraDx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LMDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LMDX

Analyst Price Target is $1.75
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for LumiraDx in the last 3 months. The average price target is $1.75, with a high forecast of $2.70 and a low forecast of $0.80. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for LMDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in LumiraDx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/28/2023Raymond JamesLower TargetOutperform ➝ Outperform$1.00 ➝ $0.80Low
5/17/2023500.comReiterated RatingMaintainsLow
5/17/2023Raymond JamesLower Target$1.50 ➝ $1.00Low
5/17/2023LADENBURG THALM/SH SHLower Target$3.80 ➝ $2.70Low
4/7/2023Raymond JamesLower TargetOutperform$2.00 ➝ $1.50N/A
3/22/2023The Goldman Sachs GroupLower TargetNeutral$1.20 ➝ $0.85Low
3/22/2023Raymond JamesLower TargetOutperform$3.50 ➝ $2.00Low
12/19/2022The Goldman Sachs GroupInitiated CoverageNeutralLow
11/11/2022Raymond JamesLower TargetOutperform$4.00 ➝ $3.50Low
8/19/2022BTIG ResearchLower TargetBuy$7.00 ➝ $4.00Low
8/19/2022Raymond JamesLower TargetOutperform$7.00 ➝ $4.00Low
5/13/2022BTIG ResearchReiterated RatingBuy$8.00Medium
5/12/2022LADENBURG THALM/SH SHLower Target$15.25 ➝ $14.00Low
3/11/2022Raymond JamesLower TargetOutperform$13.00 ➝ $9.00High
11/15/2021Evercore ISIInitiated CoverageOutperform$20.00Medium
11/12/2021BTIG ResearchReiterated RatingBuy$12.00High
10/27/2021BTIG ResearchInitiated CoverageBuy$12.00Low
10/25/2021Raymond JamesInitiated CoverageOutperformLow
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
LumiraDx logo
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.01
Low: $0.01
High: $0.02

52 Week Range

Now: N/A

Volume

132,236,800 shs

Average Volume

56,745,219 shs

Market Capitalization

$5.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Frequently Asked Questions

What sell-side analysts currently cover shares of LumiraDx?

The following sell-side analysts have issued stock ratings on LumiraDx in the last twelve months: 500.com Limited, LADENBURG THALM/SH SH, and Raymond James.
View the latest analyst ratings for LMDX.

What is the current price target for LumiraDx?

2 Wall Street analysts have set twelve-month price targets for LumiraDx in the last year. Their average twelve-month price target is $1.75. LADENBURG THALM/SH SH has the highest price target set, predicting LMDX will reach $2.70 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $0.80 for LumiraDx in the next year.
View the latest price targets for LMDX.

What is the current consensus analyst rating for LumiraDx?

LumiraDx currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LMDX will outperform the market and that investors should add to their positions of LumiraDx.
View the latest ratings for LMDX.

What other companies compete with LumiraDx?

Other companies that are similar to LumiraDx include GT Biopharma, China Pharma, Sonnet BioTherapeutics, Synaptogenix and Bright Minds Biosciences. Learn More about companies similar to LumiraDx.

How do I contact LumiraDx's investor relations team?

LumiraDx's physical mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The company's listed phone number is 354-640-0540 and its investor relations email address is [email protected]. The official website for LumiraDx is www.lumiradx.com. Learn More about contacing LumiraDx investor relations.